Clinical trial
Vaccination Priming and Vaccine Boosting Trial of Allogeneic Human GM-CSF Gene…
NCT00140374 · Cell Genesys, Industry · Completed
Key facts
| NCT number | NCT00140374 |
|---|---|
| Title | Vaccination Priming and Vaccine Boosting Trial of Allogeneic Human GM-CSF Gene Transduced Irradiated Prostate Cancer Cell Vaccines (GVAX® Vaccine for Prostate Cancer) |
| Official title | Phase I/II Study of Vaccination Priming and Vaccine Boosting With Allogeneic Human GM-CSF Gene Transduced Irradiated Prostate Cancer Cell Vaccines in Patients With Prostate Cancer |
| Lead sponsor | Cell Genesys, Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Biological |
| Interventions | Immunotherapy allogeneic GM-CSF secreting cellular vaccine |
| Enrollment | 36 |
| Start date | Dec 1, 1998 |
| Completion | Feb 1, 2001 |
| First posted | Sep 1, 2005 |
| Last update posted | Sep 1, 2005 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: